Presentation is loading. Please wait.

Presentation is loading. Please wait.

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging.

Similar presentations


Presentation on theme: "Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging."— Presentation transcript:

1 Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia Christie M. Ballantyne, MD, Joel Neutel, MD, Anne Cropp, PharmD, William Duggan, PhD, Ellen Q. Wang, PhD, David Plowchalk, PhD, Kevin Sweeney, PhD, Nitin Kaila, PhD, John Vincent, MD, PhD, Harold Bays, MD American Journal of Cardiology Volume 115, Issue 9, Pages 1212-1221 (May 2015) DOI: 10.1016/j.amjcard.2015.02.006 Copyright © 2015 The Authors Terms and Conditions Terms and Conditions

2 Figure 1 American Journal of Cardiology 2015 115, 1212-1221DOI: (10.1016/j.amjcard.2015.02.006) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions

3 Figure 2 American Journal of Cardiology 2015 115, 1212-1221DOI: (10.1016/j.amjcard.2015.02.006) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions

4 Figure 3 American Journal of Cardiology 2015 115, 1212-1221DOI: (10.1016/j.amjcard.2015.02.006) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions

5 Figure 4 American Journal of Cardiology 2015 115, 1212-1221DOI: (10.1016/j.amjcard.2015.02.006) Copyright © 2015 The Authors Terms and Conditions Terms and Conditions


Download ppt "Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging."

Similar presentations


Ads by Google